Brief: Biofrontera Inc. Announces Positive Phase 3 Results
31/10/2024 18:28
Oct 31 (Reuters) - Biofrontera Inc BFRI.O :
* BIOFRONTERA INC. ANNOUNCES HIGHLY SIGNIFICANT RESULTS IN
PHASE 3
STUDY OF AMELUZ®-PHOTODYNAMIC THERAPY (PDT) REGARDING THE
TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
* BIOFRONTERA INC - AMELUZ-PDT ACHIEVED 65.5% SUCCESS
COMPARED TO
4.8% WITH PLACEBO
* BIOFRONTERA INC: PRIMARY AND SECONDARY ENDPOINTS ALL
HIGHLY
STATISTICALLY SIGNIFICANT
Source text: ID:nGNX9Kd6ZN
Further company coverage: BFRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales